ASCENEURON

asceneuron-logo

Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimerโ€™s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases. Tauopathies are currently untreatable neurodegenerative diseases that rapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in... neurons of the brain is a common feature of tauopathies that is shared with Alzheimerโ€™s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). Due to increasing life expectancy, Alzheimerโ€™s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.

#SimilarOrganizations #People #Financial #Website #More

ASCENEURON

Social Links:

Industry:
Biotechnology Health Care Therapeutics

Founded:
2012-01-01

Address:
Lausanne, Vaud, Switzerland

Country:
Switzerland

Website Url:
http://www.asceneuron.com

Total Employee:
11+

Status:
Active

Email Addresses:
[email protected]

Total Funding:
30.85 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Content Delivery Network Domain Not Resolving Apache Euro


Similar Organizations

chimeron-bio-logo

Chimeron Bio

Chimeron Bio develops agents for personalized cancer gene therapy.

excision-biotherapeutics-logo

Excision BioTherapeutics

Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.


Current Advisors List

roel-bulthuis_image

Roel Bulthuis Chairman of the Board @ Asceneuron
Board_member

hakan-goker_image

Hakan Goker Board Director and previous acting CBO &Observer @ Asceneuron
Board_member
2013-11-01

donald-debethizy_image

Donald deBethizy Boards of Directors @ Asceneuron
Board_member

raymond-hill_image

Raymond Hill Boards of Directors @ Asceneuron
Board_member

jasper-bos_image

Jasper Bos Boards of Directors @ Asceneuron
Board_member

franz-hefti_image

Franz Hefti Boards of Directors @ Asceneuron
Board_member

frank-armstrong_image

Frank Armstrong Chairman @ Asceneuron
Board_member
2012-01-01

matthew-foy_image

Matthew Foy Investor @ Asceneuron
Board_member
2015-09-01

Current Employees Featured

dirk-beher_image

Dirk Beher
Dirk Beher Chief Executive Officer @ Asceneuron
Chief Executive Officer
2014-02-01

anna-quattropani_image

Anna Quattropani
Anna Quattropani Senior Vice-President and Head of Non-Clinical Development and Medicinal Chemistry @ Asceneuron
Senior Vice-President and Head of Non-Clinical Development and Medicinal Chemistry
2018-05-01

bruno-permanne_image

Bruno Permanne
Bruno Permanne Senior Director and Head of Biology @ Asceneuron
Senior Director and Head of Biology
2013-01-01

deborah-harland_image

Deborah Harland
Deborah Harland Non Executive Director @ Asceneuron
Non Executive Director
2015-09-01

Founder


dirk-beher_image

Dirk Beher

Investors List

the-michael-j-fox-foundation_image

Michael J. Fox Foundation

Michael J. Fox Foundation investment in Grant - Asceneuron

the-michael-j-fox-foundation_image

Michael J. Fox Foundation

Michael J. Fox Foundation investment in Grant - Asceneuron

johnson-johnson-innovation_image

Johnson & Johnson Innovation

Johnson & Johnson Innovation investment in Series A - Asceneuron

sr-one_image

SR One

SR One investment in Series A - Asceneuron

sofinnova-partners_image

Sofinnova Partners

Sofinnova Partners investment in Series A - Asceneuron

merckventures_image

M Ventures

M Ventures investment in Series A - Asceneuron

kurma-life-science-partners_image

Kurma Partners

Kurma Partners investment in Series A - Asceneuron

Official Site Inspections

http://www.asceneuron.com Semrush global rank: 8.65 M Semrush visits lastest month: 274

  • Host name: qx2.tophost.ch
  • IP address: 194.150.248.33
  • Location: Switzerland
  • Latitude: 47.1449
  • Longitude: 8.1551
  • Timezone: Europe/Zurich

Loading ...

More informations about "Asceneuron" on Search Engine